Although when compared to placebo tralokinumab did not affect symptom score assessed by the Asthma Control Questionnaire (ACQ), this anti-IL-13 drug reduced the need for rescue medication and significantly improved lung function by eliciting percentage increases in FEV1 from baseline ranging from 8.1% (150 mg) to 16.1% (600 mg) [80]. The gene discussed is IL13; the disease is asthma.